HoyleCohen’s Rocket Pharmaceuticals RCKT Stock Holding History

HoyleCohen’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,000	Closed	-$52K	–	159
2017 Q4	$52K	Buy	+5,000	New	+$49.6K	0.01%	152

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HoyleCohen's RCKT Position: Q1 2018 in Review

HoyleCohen sold out of Rocket Pharmaceuticals (RCKT) in Q1 2018, closing a stake of 5,000 shares — an estimated $52K sold.

HoyleCohen first reported a position in RCKT in Q4 2017 and held it in 1 quarter. The position peaked at $52K in Q4 2017. 56 funds tracked by Wall St. Rank hold RCKT as of Q1 2018.

HoyleCohen reported no remaining Rocket Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
HoyleCohen sold 5,000 Rocket Pharmaceuticals shares in Q1 2018, an estimated $52K.
HoyleCohen first reported a position in Rocket Pharmaceuticals in Q4 2017 and held it in 1 quarter.
HoyleCohen's Rocket Pharmaceuticals position peaked at $52K in Q4 2017.
56 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2018.

Based on HoyleCohen's 13F filing for Q1 2018, filed 15 May 2018.